85%Confidence
0Views
FDASource
2026-03-24Date
Summary
Zydus Pharmaceuticals faces a Class II FDA recall for Icosapent Ethyl Capsules due to oxidation causing visible defects, indicating potential quality control failures in manufacturing or supply chain. This could impact patient safety, brand reputation, and may lead to increased regulatory scrutiny for Zydus and its contract manufacturer Softgel Healthcare.
Actionable: Monitor Zydus Pharmaceuticals for potential financial impacts from recall costs, regulatory actions, and competitor gains in the cardiovascular drug market.
AI Confidence: 85%
Data Points
firmZydus Pharmaceuticals (USA) Inc
classificationClass II
statusOngoing
distributionNationwide in the USA
productIcosapent Ethyl Capsules, 1 gram, 120 Capsules per bottle, Rx only, Manufactured by: Softgel Healthcare Pvt. Ltd., India; Distributed by: Zydus Pharma
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now